nach oben

Erschienen in:

01.12.2018 | Review Article

Contemporary treatment of metastatic renal cell carcinoma

verfasst von: Pawel Wiechno, Jakub Kucharz, Malgorzata Sadowska, Wojciech Michalski, Bozena Sikora-Kupis, Joanna Jonska-Gmyrek, Grazyna Poniatowska, Karol Nietupski, Krzysztof Ossolinski, Tomasz Demkow

Erschienen in: Medical Oncology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Renal cell carcinoma is the 14th most common cancer worldwide. It is a heterogeneous group of histopathological entities, of which the most common is clear cell renal cell carcinoma. Approximately 20–30% of patients present initially with metastatic disease and an additional 20% will progress after radical surgical treatment. Metastatic disease that is non-feasible for surgical treatment remains incurable. Numerous studies have demonstrated that—with the introduction of new drugs—the treatment outcomes of metastatic disease have improved. The development of new therapies as well as the optimization and individualization of procedures allow us to hope for further progress in this area.

Muglia VF, Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras. 2015 48(3):166–74. https://doi.org/10.1590/01003984.2013.1927.CrossRefPubMedPubMedCentral

Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010 46(4):765–81. https://doi.org/10.1016/j.ejca.2009.12.014.CrossRefPubMed

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 127(12):2893–917. https://doi.org/10.1002/ijc.25516.CrossRefPubMed

Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA. The epidemiology of renal cell carcinoma. Eur Urol. 2011 60(4):615–21. https://doi.org/10.1016/j.eururo.2011.06.049.CrossRefPubMed

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Gruenvald V, Horwich A, ESMO Guidelines Committee. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 27(suppl 5):v58–68.CrossRefPubMed

Mittal K, Koon H, Elson P, Triozzi P, Dowlati A, Chen H, Borden EC, Rini BI. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers. Cancer Biol Ther. 2014 15(8):975–81. https://doi.org/10.4161/cbt.29187.CrossRefPubMedPubMedCentral

Pfaffenroth EC, Linehan WM. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther. 2008 8(6):779–90. https://doi.org/10.1517/14712598.8.6.779.CrossRefPubMedPubMedCentral

Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, Nagashima Y, Kitamura H, Latif F, Zbar B, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 1994 54(11):2852–5.PubMed

Coleman JA. Familial and hereditary renal cancer syndromes. Urol Clin N Am. 2008 35(4):563–72. https://doi.org/10.1016/j.ucl.2008.07.014.CrossRef

10.

Athar U, Gentile TC. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 2008 15(2):3954–66.PubMed

11.

Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008 34(3):193–205. https://doi.org/10.1016/j.ctrv.2007.12.001.CrossRefPubMed

12.

Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003 97(7):1663–71.CrossRefPubMed

13.

Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI. Distribution ofmetastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012 23(4):973–80. https://doi.org/10.1093/annonc/mdr362.CrossRefPubMed

14.

Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 17(8):2530–40.CrossRefPubMed

15.

Motzer RJ, Escudier B, Bukowski R, Rini BI, Hutson TE, Barrios CH, Lin X, Fly K, Matczak E, Gore ME. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer. 2013 108(12):2470–7. https://doi.org/10.1038/bjc.2013.236.CrossRefPubMedPubMedCentral

16.

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 27(34):5794–9. https://doi.org/10.1200/JCO.2008.21.4809.CrossRefPubMed

17.

Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013 14(2):141–8. https://doi.org/10.1016/S1470-2045(12)70559-4.CrossRefPubMedPubMedCentral

18.

Kubackova K, Melichar B, Bortlicek Z, Pavlik T, Poprach A, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Prausova J, Buchler T, Czech Renal Cancer Cooperative Group. Comparison of two prognostic models in patients with metastatic renal cancer treated with Sunitinib: a retrospective, registry-based study. Target Oncol. 2015 10(4):557–63. https://doi.org/10.1007/s11523-015-0366-9.CrossRefPubMed

19.

Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001 345(23):1655–9.CrossRefPubMed

20.

Conti SL, Thomas IC, Hagedorn JC, Chung BI, Chertow GM, Wagner TH, Brooks JD, Srinivas S, Leppert JT. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer. 2014 134(9):2245–52.CrossRefPubMedPubMedCentral

21.

Mejean A, Escudier B, Thezenas S, Beauval JB, Geoffroy L, Bensalah K, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Timsit MO, Albiges L, Beisland C, Aitchison M, Colas S, Lebret T, Ravaud A. CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—results of a phase III noninferiority trial. J Clin Oncol. 2018 36(18_suppl): LBA3–LBA3.CrossRef

22.

Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TB, Canfield SE, Staehler M, Powles T, Ljungberg B, Bex A. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014 15(12):e549-61. https://doi.org/10.1016/S1470-2045(14)70235-9.CrossRefPubMed

23.

Dabestani S, Marconi L, Bex A. Metastasis therapies for renal cancer. Curr Opin Urol. 2016 26(6):566–72.CrossRefPubMed

24.

Marulli G, Sartori F, Bassi PF, dal Moro F, Gino Favaretto A, Rea F. Long-term results of surgical management of pulmonary metastases from renal cell carcinoma. Thorac Cardiovasc Surg. 2006 54(8):544–7.CrossRefPubMed

25.

Meimarakis G, Angele M, Staehler M, Clevert DA, Crispin A, Rüttinger D, Löhe F, Preissler G, Hatz RA, Winter H. Evaluation of a new prognostic score (Munich score) to predict long term survival after resection of pulmonary renal cell carcinoma metastases. Am J Surg. 2011 202(2):158–67. https://doi.org/10.1016/j.amjsurg.2010.06.029.CrossRefPubMed

26.

Murthy SC, Kim K, Rice TW, Rajeswaran J, Bukowski R, DeCamp MM, Blackstone EH. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg. 2005 79(3):996–1003.CrossRefPubMed

27.

Pogrebniak HW, Haas G, Linehan WM, Rosenberg SA, Pass HI. Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg. 1992 54(1):33–8. Review.CrossRefPubMed

28.

Pfannschmidt J, Klode J, Muley T, Dienemann H, Hoffmann H. Nodal involvement at the time of pulmonary metastasectomy: experiences in 245 patients. Ann Thorac Surg. 2006 81(2):448–54.CrossRefPubMed

29.

Piltz S, Meimarakis G, Wichmann MW, Hatz R, Schildberg FW, Fuerst H. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg. 2002 73(4):1082–7.CrossRefPubMed

30.

Ippen FM, Mahadevan A, Wong ET, Uhlmann EJ, Sengupta S, Kasper EM. Stereotactic radiosurgery for renal cancer brain metastasis: prognostic factors and the role of whole-brain radiation and surgical resection. J Oncol. 2015;2015:636918. https://doi.org/10.1155/2015/636918.CrossRefPubMedPubMedCentral

31.

Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N. AVOREN trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007 370(9605):2103–11.CrossRefPubMed

32.

Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 28(13):2137–43. https://doi.org/10.1200/JCO.2009.26.5561.CrossRefPubMedPubMedCentral

33.

Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 27(8):1280–9. https://doi.org/10.1200/JCO.2008.19.3342.CrossRefPubMed

34.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009 27(20):3312–8. https://doi.org/10.1200/JCO.2008.19.5511.CrossRefPubMed

35.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 356(2):115–24.CrossRefPubMed

36.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 27(22):3584–90. https://doi.org/10.1200/JCO.2008.20.1293.CrossRefPubMedPubMedCentral

37.

Larkin J, Paine A, Foley G, Mitchell S, Chen C. First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis. Expert Opin Pharmacother. 2015;16(13):1915–27. https://doi.org/10.1517/14656566.2015.1058359.CrossRefPubMed

38.

Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ, et al. Adjuvant Sunitinib in high-risk renal-cell carcinoma after Nephrectomy. N Engl J Med. 2016 375(23):2246–54.CrossRefPubMed

39.

Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016 387(10032):2008–16. https://doi.org/10.1016/S0140-6736(16)00559-6.CrossRefPubMedPubMedCentral

40.

Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010 28(6):1061–8. https://doi.org/10.1200/JCO.2009.23.9764.CrossRefPubMed

41.

Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 369(8):722–31. https://doi.org/10.1056/NEJMoa1303989.CrossRefPubMed

42.

Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014 32(14):1412–8. https://doi.org/10.1200/JCO.2013.50.8267.CrossRefPubMed

43.

Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, et al. Randomized phase III trial of adjuvant Pazopanib versus Placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol. 2017 35(35):3916–3923. https://doi.org/10.1200/JCO.2017.73.5324.CrossRefPubMedPubMedCentral

44.

Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011 378(9807):1931–9. https://doi.org/10.1016/S0140-6736(11)61613-9.CrossRefPubMed

45.

Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, Tomczak P, Lyulko O, Alyasova A, Harza M, Kogan M, Alekseev BY, Sternberg CN, Szczylik C, Cella D, Ivanescu C, Krivoshik A, Strahs A, Esteves B, Berkenblit A, Hutson TE. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013 31(30):3791–9. https://doi.org/10.1200/JCO.2012.47.4940.CrossRefPubMedPubMedCentral

46.

Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015 16(15):1473–82. https://doi.org/10.1016/S1470-2045(15)00290-9.CrossRefPubMed

47.

Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 17(7):917–27. https://doi.org/10.1016/S1470-2045(16)30107-3.CrossRefPubMed

48.

Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 94:115–25. https://doi.org/10.1016/j.ejca.2018.02.012.CrossRefPubMedPubMedCentral

49.

Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006 12(1):122–7.CrossRefPubMed

50.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 356(22):2271–81.CrossRefPubMed

51.

Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008 372(9637):449–56. https://doi.org/10.1016/S0140-6736(08)61039-9.CrossRefPubMed

52.

Finke J, Ferrone S, Frey A, Mufson A, Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today. 1999 20(4):158–60.CrossRefPubMed

53.

Medical Research Council Renal Cell Collaborators. Medical Research Council (MRC) Renal Cell Collaboration. Interferon-∝ and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet. 1999;353(9146):14–7.

54.

Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000 6(Suppl 1):55-7.

55.

Zitvogel L, Kroemer G. Targeting. PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012 1(8):1223–1225.CrossRefPubMedPubMedCentral

56.

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 373(19):1803–13. https://doi.org/10.1056/NEJMoa1510665.CrossRefPubMedPubMedCentral

57.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 378(14):1277–90. https://doi.org/10.1056/NEJMoa1712126.CrossRefPubMedPubMedCentral

58.

Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009 10(8):757–63. https://doi.org/10.1016/S1470-2045(09)70162-7.CrossRefPubMed

59.

Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM, ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010 116(5):1272–80. https://doi.org/10.1002/cncr.24864.CrossRefPubMed

60.

Dudek AZ, Raza A, Chi M, Singhal M, Oberoi R, Mittapalli RK, Agarwal S, Elmquist WF. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer. 2013 11(2):155–60. https://doi.org/10.1016/j.clgc.2012.11.001.CrossRefPubMed

61.

Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol. 2010 21(5):1027–31. https://doi.org/10.1093/annonc/mdp411.CrossRefPubMed

62.

Calvo E, Schmidinger M, Heng DY, Grünwald V, Escudier B. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat Rev. 2016 50:109–117. https://doi.org/10.1016/j.ctrv.2016.09.002.CrossRefPubMed

Titel: Contemporary treatment of metastatic renal cell carcinoma
verfasst von: Pawel Wiechno
Jakub Kucharz
Malgorzata Sadowska
Wojciech Michalski
Bozena Sikora-Kupis
Joanna Jonska-Gmyrek
Grazyna Poniatowska
Karol Nietupski
Krzysztof Ossolinski
Tomasz Demkow
Publikationsdatum: 01.12.2018
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 12/2018
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-018-1217-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Contemporary treatment of metastatic renal cell carcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2018

Letter to the editor regarding “Ultrasound features of breast cancer for predicting axillary lymph node metastasis”

Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients

Testicular teratomas: a growing problem?

Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer

The use of radiofrequency ablation in pancreatic cancer in the midst of the dawn of immuno-oncology

Duration of adjuvant immunotherapy—biologic, clinical and economic considerations

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie